Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2011

01-11-2011 | Epidemiology

Absenteeism and short-term disability associated with breast cancer

Authors: Alex Z. Fu, Lei Chen, Sean D. Sullivan, Neal P. Christiansen

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

Few data exist related to the impact of breast cancer on work absenteeism and short-term disability. This retrospective study estimated the extent and costs of breast cancer-associated production loss using a large medical and pharmacy claims database from a US commercially insured population between January 2003 and December 2007. Women aged ≥18 years with ≥2 breast cancer diagnoses within 90 days were selected. Controls were matched to cases based on index date (first breast cancer diagnosis), age, region, employer, and health insurance type. Outcomes were days absent from work and days with short-term disability. Costs were estimated using daily wage rates. 856 and 2,668 patients were selected for absenteeism and short-term disability, respectively, with a mean age of 49 and 50 years. Average number of absenteeism days was 35 and 21, and short-term disability days were 51 and 5, for cases and controls, respectively, within the post-index year (both P < 0.001). Adjusted incremental costs for absenteeism and short-term disability were $1,911 and $6,157 (P < 0.001), respectively, per breast cancer patient per year. This study suggests that breast cancer is associated with work-related productivity loss within the first year of diagnosis that may be a substantial cost to employers.
Literature
4.
go back to reference Campbell JD, Ramsey SD (2009) The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 27:199–209PubMedCrossRef Campbell JD, Ramsey SD (2009) The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 27:199–209PubMedCrossRef
5.
go back to reference Berkowitz N, Gupta S, Silberman G (2000) Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 3:23–30PubMedCrossRef Berkowitz N, Gupta S, Silberman G (2000) Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 3:23–30PubMedCrossRef
6.
go back to reference Barron JJ, Quimbo R, Nikam PT, Amonkar MM (2008) Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 109:367–377PubMedCrossRef Barron JJ, Quimbo R, Nikam PT, Amonkar MM (2008) Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 109:367–377PubMedCrossRef
7.
go back to reference Rao S, Kubisiak J, Gilden D (2004) Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 83:25–32PubMedCrossRef Rao S, Kubisiak J, Gilden D (2004) Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 83:25–32PubMedCrossRef
8.
go back to reference Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D (2006) Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer 106:1875–1882PubMedCrossRef Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D (2006) Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer 106:1875–1882PubMedCrossRef
9.
go back to reference Hensley ML, Dowell J, Herndon JE 2nd, Winer E, Stark N, Weeks JC, Paskett E (2005) Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat 91:153–161PubMedCrossRef Hensley ML, Dowell J, Herndon JE 2nd, Winer E, Stark N, Weeks JC, Paskett E (2005) Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat 91:153–161PubMedCrossRef
10.
go back to reference Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ (1996) Cost of breast cancer treatment. A 4 year longitudinal study. Arch Intern Med 156:2197–2201PubMedCrossRef Legorreta AP, Brooks RJ, Leibowitz AN, Solin LJ (1996) Cost of breast cancer treatment. A 4 year longitudinal study. Arch Intern Med 156:2197–2201PubMedCrossRef
11.
go back to reference Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML (2008) Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 100:1763–1770PubMedCrossRef Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML (2008) Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 100:1763–1770PubMedCrossRef
12.
go back to reference Max W, Sung HY, Stark B (2009) The economic burden of breast cancer in California. Breast Cancer Res Treat 116:201–207PubMedCrossRef Max W, Sung HY, Stark B (2009) The economic burden of breast cancer in California. Breast Cancer Res Treat 116:201–207PubMedCrossRef
13.
go back to reference Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M (2000) The costs of cancer to a major employer in the United States: a case–control analysis. Am J Manag Care 6:1243–1251PubMed Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M (2000) The costs of cancer to a major employer in the United States: a case–control analysis. Am J Manag Care 6:1243–1251PubMed
14.
go back to reference Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D (2005) Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Women’s Health Issues 15:97–108PubMedCrossRef Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D (2005) Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Women’s Health Issues 15:97–108PubMedCrossRef
15.
go back to reference Bloom BS (2004) Prevalence and economic effects of depression. Manag Care 13(6 suppl):9–16PubMed Bloom BS (2004) Prevalence and economic effects of depression. Manag Care 13(6 suppl):9–16PubMed
16.
go back to reference Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000. J Clin Psychiatry 64:1465–1475PubMedCrossRef Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000. J Clin Psychiatry 64:1465–1475PubMedCrossRef
17.
go back to reference Zhao Y, Ash AS, Ellis RP, Ayanian JZ, Pope GC, Bowen B, Weyuker L (2005) Predicting pharmacy costs and other medical costs using diagnosis and drug claims. Public Health Rep 116:45–50 Zhao Y, Ash AS, Ellis RP, Ayanian JZ, Pope GC, Bowen B, Weyuker L (2005) Predicting pharmacy costs and other medical costs using diagnosis and drug claims. Public Health Rep 116:45–50
20.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8–27PubMedCrossRef Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8–27PubMedCrossRef
21.
go back to reference Comorbidity software version 3.4 (2009) Rockville, MD: Agency for Healthcare Research and Quality Comorbidity software version 3.4 (2009) Rockville, MD: Agency for Healthcare Research and Quality
22.
go back to reference Box GEP, Cox DR (1964) An analysis of transformation. J R Stat Soc B 26:211–253 Box GEP, Cox DR (1964) An analysis of transformation. J R Stat Soc B 26:211–253
23.
go back to reference Duan N (1983) Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 78:605–610CrossRef Duan N (1983) Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 78:605–610CrossRef
24.
go back to reference Manning WG (1998) The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 17:283–295PubMedCrossRef Manning WG (1998) The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 17:283–295PubMedCrossRef
25.
go back to reference Duan N, Manning WG, Morris CN, Newhouse JP (1983) A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1:115–126CrossRef Duan N, Manning WG, Morris CN, Newhouse JP (1983) A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1:115–126CrossRef
26.
go back to reference Fu AZ, Kattan MW (2006) Racial and ethnic differences in preference-based health status measure. Curr Med Res Opin 22:2439–2448PubMedCrossRef Fu AZ, Kattan MW (2006) Racial and ethnic differences in preference-based health status measure. Curr Med Res Opin 22:2439–2448PubMedCrossRef
27.
go back to reference McCullagh P, Nelder JA (1989) Generalized linear model. New York, Chapman and Hall McCullagh P, Nelder JA (1989) Generalized linear model. New York, Chapman and Hall
28.
go back to reference Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY (1999) Methods for analyzing health care utilization and costs. Annu Rev Public Health 20:125–144PubMedCrossRef Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY (1999) Methods for analyzing health care utilization and costs. Annu Rev Public Health 20:125–144PubMedCrossRef
29.
go back to reference Park RE (1966) Estimation with heteroskedastic error terms. Econometrica 34:888CrossRef Park RE (1966) Estimation with heteroskedastic error terms. Econometrica 34:888CrossRef
30.
go back to reference Manning WG, Mullahy J (2001) Estimating log models: to transform or not to transform? J Health Econ 20:461–494PubMedCrossRef Manning WG, Mullahy J (2001) Estimating log models: to transform or not to transform? J Health Econ 20:461–494PubMedCrossRef
31.
go back to reference Fu AZ, Wang N (2008) Healthcare expenditure and patient satisfaction: cost and quality from the consumer’s perspective in the United States. Curr Med Res Opin 24:1385–1394PubMedCrossRef Fu AZ, Wang N (2008) Healthcare expenditure and patient satisfaction: cost and quality from the consumer’s perspective in the United States. Curr Med Res Opin 24:1385–1394PubMedCrossRef
32.
go back to reference Fu AZ, Qiu Y, Radican L, Wells BJ (2009) Healthcare and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diab Care 32:2187–2192CrossRef Fu AZ, Qiu Y, Radican L, Wells BJ (2009) Healthcare and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diab Care 32:2187–2192CrossRef
33.
go back to reference Broekx S, Hond ED, Torfs R, Remacle A, Mertens R, D’Hooghe T, Neven P, Christiaens MR, Simoens S (2010) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. doi:10.1007/s10198-010-0237-3 Broekx S, Hond ED, Torfs R, Remacle A, Mertens R, D’Hooghe T, Neven P, Christiaens MR, Simoens S (2010) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. doi:10.​1007/​s10198-010-0237-3
34.
go back to reference Gordon L, Scuffham P, Hayes S, Newman B (2007) Exploring the economic impact of breast cancers during the 18 months following diagnosis. Psychooncology 16:1130–1139PubMedCrossRef Gordon L, Scuffham P, Hayes S, Newman B (2007) Exploring the economic impact of breast cancers during the 18 months following diagnosis. Psychooncology 16:1130–1139PubMedCrossRef
35.
go back to reference Lidgren M, Wilking N, Jönsson B (2007) Cost of breast cancer in Sweden in 2002. Eur J Health Econ 8:5–15PubMedCrossRef Lidgren M, Wilking N, Jönsson B (2007) Cost of breast cancer in Sweden in 2002. Eur J Health Econ 8:5–15PubMedCrossRef
36.
go back to reference Albain KS, Paik S, van’t Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(suppl 3):S141–S145PubMedCrossRef Albain KS, Paik S, van’t Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(suppl 3):S141–S145PubMedCrossRef
Metadata
Title
Absenteeism and short-term disability associated with breast cancer
Authors
Alex Z. Fu
Lei Chen
Sean D. Sullivan
Neal P. Christiansen
Publication date
01-11-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1541-z

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine